Please login to the form below

Not currently logged in
Email:
Password:

Bausch & Lomb allows bid rival to discuss offer with shareholders

Bausch & Lomb grants rival bidder Advanced Medical Optics (AMO) ìlimited permissionî to discuss its USD 4.2bn take over offer with selected shareholders

Bausch & Lomb has granted rival bidder Advanced Medical Optics (AMO) ìlimited permissionî to discuss its USD 4.2bn take over offer with selected shareholders.

The German ophthalmology company is staying with the original USD 3.7bn buyout deal from New York-based private equity firm, Warburg Pincus.

Bausch & Lomb says it is 'uncertain' that Advanced Medical Optics, which is the third largest lens solution manufacturer after Alcon and Bausch & Lomb, could win shareholder approval for its cash-and-stock counter bid.

Advanced Medical's third-largest shareholder, San Francisco-headquartered ValueAct Capital, has already opposed the takeover.

According to media reports, Bausch & Lomb has continued to recommend the pending purchase offer from Warburg Pincus in a letter from the board sent on 29 July to Advanced Medical's CEO, James V Mazzo.

The letter gives Advanced Medical until 12pm on 3 August to provide evidence of its ability to secure approval from stockholders.

31st July 2007

Share

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Genesis Research

Genesis Research is an international HEOR and RWE research organization. A leader in evidence strategy, generation and communication, the company...

Latest intelligence

Lifting the fog to help Clinical Labs navigate IVDR 2022
In Vitro Diagnostic Regulation (IVDR 2022) was on the horizon: a new regulatory basis for laboratories to adhere to regarding their diagnostic equipment and tests. BD wanted to let their...
Empowering adolescents to manage emotional and mental health issues
1 in 10 UK children suffer with a mental health issue and alarmingly as many as 70% of these don’t receive the proper support they need. That’s why The Anna...
Reframing rare to increase earlier diagnosis of Gaucher Disease
Sanofi Genzyme wanted to reach haematologists; the specialist physicians most likely to encounter patients with Gaucher Disease prior to diagnosis. The problem? Gaucher Disease is considered very rare and its...